Portland, OR, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Antiplatelet Market by Drug Class (Adenosine diphosphate (ADP) receptor inhibitors, Irreversible inhibitors cyclooxygenase, and Others), by Route of Administration, (Oral and Injectable), and by Distribution Channel, (Hospital pharmacies, Drug store and retail pharmacies, and Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global antiplatelet industry generated $3.8 billion in 2022, and is anticipated to generate $5.8 billion by 2032, witnessing a CAGR of 4.2% from 2023 to 2032.
Antiplatelets are pharmaceutical agents that inhibit the aggregation of platelets, thereby impeding the formation of blood clots. These medications are frequently prescribed to individuals who are susceptible to experiencing a cardiovascular disease or cerebrovascular accident.They are also capable of alleviating symptoms like chest discomfort, inadequate blood flow, and difficulty in breathing. Antiplatelet reacts with the proteins that promote blood clotting and slows down the process of clot formation.
Request Sample of the Report: https://www.alliedmarketresearch.com/request-sample/10844
Prime determinants of growth
Rise in prevalence of cardiovascular diseases such as coronary artery disease, myocardial infarction (heart attack), ischemic stroke, and peripheral arterial disease, rise in research and development activities, and rise in the geriatric population drive the growth of the global antiplatelet market. However, the side effects associated with the antiplatelets restrict market growth. Moreover, growth opportunities in emerging markets such as increase in incidence of cardiovascular diseases and rise in healthcare spending for cardiovascular diseases presents new opportunities in the coming years.
Report coverage & details:
| Report Coverage | Details |
| Forecast Period | 2023–2032 |
| Base Year | 2022 |
| Market Size in 2022 | $3.8 billion |
| Market Size in 2032 | $5.8 billion |
| CAGR | 4.2% |
| No. of Pages in Report | 285 |
| Segments covered | Drug Class, Route of Administration, Distribution Channel, and Region. |
| Drivers | Rise in prevalence of cardiovascular diseases Rise in R&D activities Rise in geriatric population |
| Opportunities | Growth opportunities in emerging markets |
| Restraints | Side effects of antiplatelets |
Covid-19 Scenario
- COVID-19 pandemic had a moderate positive effect on the global antiplatelet market owing to antiplatelet medications used in combination with anticoagulants to provide comprehensive thromboprophylaxis or treatment in specific cases. This had contributed to an increased utilization of antiplatelet drugs in the management of COVID-19 patients.
- Furthermore, the antiplatelet market observed significant growth during the post-pandemic period owing to a rise in the number of cardiovascular disease cases. In addition, an increase in awareness about early diagnosis and treatment and rise in R&D activities for cardiovascular diseases support the market growth.
Procure Complete Report at 20% Discount (285 Pages PDF with Insights, Charts, Tables, and Figures)
https://www.alliedmarketresearch.com/checkout-final/antiplatelet-market
The adenosine diphosphate (ADP) receptor inhibitors segment to maintain its leadership status throughout the forecast period
Based on drug class, the adenosine diphosphate (ADP) receptor inhibitors segment held the largest market share in 2022, accounting for more than two-thirds of the global antiplatelet market revenue and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 4.4% from 2023 to 2032, owing to high adoption of ADP receptors as they have high effectiveness in preventing platelet aggregation and reduces the risk of cardiovascular events.
The oral segment to maintain its leadership status throughout the forecast period
Based route of administration, the oral segment held the largest market share in 2022, accounting for more than 90% of the global antiplatelet market and is estimated to maintain its leadership status throughout the forecast period. This segment is projected to manifest the highest CAGR of 4.2% from 2023 to 2032, owing to surge in high adoption of oral drugs, such as aspirin, which are less expensive than other route drugs, easy to administer and most of the antiplatelet drugs are available in oral form.
The drug stores and retail pharmacies segment to maintain its lead position during the forecast period
Based on distribution channel, the drug stores and retail pharmacies segment accounted for the largest share in 2022, contributing to nearly two-thirds of the global antiplatelet market revenue, and is projected to maintain its lead position during the forecast period. This is attributed to high accessibility, and making it convenient for patients to access antiplatelet medications easily. However, the hospitals and clinical testing laboratories segment is expected to witness the fastest CAGR of 5.3% from 2023 to 2032. This is attributed to growing adoption of e-commerce and digital platforms has made it easier for patients to order medications online from the comfort of their homes, enhancing convenience and accessibility for antiplatelet drugs.
For Purchase Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/10844
North America to maintain its dominance by 2032
Based on region, North America held the largest market share in terms of revenue in 2022, accounting for nearly two-fifths of the global antiplatelet market revenue and is likely to dominate the market during the forecast period. Easy availability of products for treatment, well-developed healthcare infrastructure, and rise in prevalence of cardiovascular diseases such as stroke promoted the growth of the antiplatelet market in North America.
However, the Asia-Pacific region is expected to witness the fastest CAGR of 4.9% from 2023 to 2032. High prevalence of geriatric population with increase in need of diagnostic procedures, surge in prevalence of cardiovascular diseases, rise in research and development activities in fields such as pharmaceuticals, and life sciences and surge in healthcare expenditure in the Asia-Pacific region, is expected to drive the growth of the antiplatelet market.
Leading Market Players: -
- A Becton, Dickinson and Company
- AstraZeneca plc
- Bayer AG
- Eli Lilly and Company
- Glenmark Pharmaceuticals Limited
- Cipla Ltd.
- Otsuka Pharmaceutical Co., Ltd.
- Lupin
- Sanofi S.A.
- Daiichi Sankyo Company Limited
- Chiesi Farmaceutici S.p.A.
The report provides a detailed analysis of these key players in the global antiplatelet market. These players have adopted strategy such as product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Browse More Trending Reports in Healthcare Industry By AMR
The global extremity reconstruction market was valued at $3.6 billion in 2020, and is projected to reach $6.5 billion by 2030, growing at a CAGR of 6.3% from 2021 to 2030.
The global automated radiosynthesis module market size was valued at $27.92 Million in 2020, and is projected to reach $ 45.93 Million by 2030, registering a CAGR of 5.1% from 2021 to 2030.
The global medical radiation detection market size was valued at $1,173.0 million in 2020, and is projected to reach $2,558.1 million by 2030, registering a CAGR of 8.4% from 2021 to 2030.
The global advanced drug delivery market size was valued at $44,029.59 million in 2020, and is projected to reach $1,95,132.45 million by 2030, registering a CAGR of 16.0% from 2021 to 2030.
The global bone growth stimulators market size was valued at $2.0 billion in 2020, and is projected to reach $3.3 billion by 2030, growing at a CAGR of 5.5% from 2021 to 2030.
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
